Alpha DaRT's ReSTART pivotal readout will decide whether a Japan-approved, BTD-laden platform earns U.S. PMA or stalls on single-arm cSCC data

Bull

A positive readout would require a statistically compelling ORR with durable responses meeting the six-month DOR co-primary endpoint, likely at or above the historical benchmark for recurrent cSCC treatments, validating the single-arm trial design acceptable to FDA. Success would support PMA submission completion, establish the first U.S. approved indication beyond the Japan label, and de-risk the broader platform across glioblastoma, pancreatic cancer, and HNSCC by demonstrating regulatory executability under PMA-level evidence standards.

Bear

The most likely failure mode is a response rate that falls short of the pre-specified performance goal or responses that are insufficiently durable to satisfy the six-month DOR co-primary endpoint in the single-arm design — particularly since a single-arm study without a concurrent control arm faces heightened FDA scrutiny on effect size magnitude. A secondary concern is that immunocompromised patients (enrolled in ADMIRE but overlapping in profile with ReSTART subjects) may show heterogeneous response patterns, and any signal of systemic toxicity or inadequate local control could prompt FDA to request a randomized confirmatory study before granting PMA, stalling the U.S. commercial launch.